Novel sesquiterpenoid stat3 inhibitors
US-2016137663-A1 · May 19, 2016 · US
Stat degraders and uses thereof
US11746120B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11746120-B2 |
| Application number | US-202218045390-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 10, 2022 |
| Priority date | Apr 5, 2019 |
| Publication date | Sep 5, 2023 |
| Grant date | Sep 5, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds, compositions thereof, and methods of using the same.
First claim
Opening claim text (preview).
We claim: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 6. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 8. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 9. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 10. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 11. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 12. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 13. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 14. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 15. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 16. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 17. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 18. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 19. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 20. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 21. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 22. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 23. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 24. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 25. The compound of claim 1 , wherein said compound is or a pharmaceutically acceptable salt thereof. 26. A pharmaceutical composition comprising a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 27. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 28. The pharmaceutical composition of cla
Assignees
Inventors
Classifications
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
- C07K5/06034Primary
the side chain containing 2 to 4 carbon atoms · CPC title
- C07F9/6561Primary
containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11746120B2 cover?
- The present invention provides compounds, compositions thereof, and methods of using the same.
- Who is the assignee on this patent?
- Kymera Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K5/06034. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).